Repressive PPARγ modulators acting as inverse agonists are suggested as promising therapeutic options in obesity management and are associated with enhancement in bone formation and improved WAT metabolic functions [9,48,59,60]. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.